Sylwia Chocholska

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4790151/publications.pdf

Version: 2024-02-01

44	667	567144 15	610775 24
papers	citations	h-index	g-index

47	47	47	1326
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Molecular cytogenetic analysis of a familial interstitial deletion Xp22.2-22.3 with a highly variable phenotype in female carriers. American Journal of Medical Genetics, Part A, 2006, 140A, 604-610.	0.7	69
2	Th17/IL-17A Might Play a Protective Role in Chronic Lymphocytic Leukemia Immunity. PLoS ONE, 2013, 8, e78091.	1.1	47
3	BAFF and APRIL expression in B-cell chronic lymphocytic leukemia: Correlation with biological and clinical features. Leukemia Research, 2009, 33, 1319-1327.	0.4	44
4	Assessment of red blood cell distribution width as a prognostic marker in chronic lymphocytic leukemia. Oncotarget, 2016, 7, 32846-32853.	0.8	44
5	Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients. Hematological Oncology, 2013, 31, 41-48.	0.8	39
6	Expression of Programmed Death 1 Ligand in Different Compartments of Chronic Lymphocytic Leukemia. Acta Haematologica, 2015, 134, 255-262.	0.7	38
7	Resveratrol increases rate of apoptosis caused by purine analogues in malignant lymphocytes of chronic lymphocytic leukemia. Annals of Hematology, 2011, 90, 173-183.	0.8	35
8	Simvastatin and purine analogs have a synergic effect on apoptosis of chronic lymphocytic leukemia cells. Annals of Hematology, 2010, 89, 1115-1124.	0.8	30
9	The clinical significance of interleukin 18 assessment in sarcoidosis patients. Respiratory Medicine, 2007, 101, 722-728.	1.3	29
10	Changes in T-cell subpopulations and cytokine network during early period of ibrutinib therapy in chronic lymphocytic leukemia patients: the significant decrease in T regulatory cells number. Oncotarget, 2017, 8, 34661-34669.	0.8	28
11	CD1d expression is higher in chronic lymphocytic leukemia patients with unfavorable prognosis. Leukemia Research, 2014, 38, 435-442.	0.4	25
12	ACE Insertion/Deletion Polymorphism (rs4646994) Is Associated With the Increased Risk of Multiple Myeloma. Frontiers in Oncology, 2019, 9, 44.	1.3	24
13	The Association of GSTT1, GSTM1, and TNF-Î± Polymorphisms With the Risk and Outcome in Multiple Myeloma. Frontiers in Oncology, 2019, 9, 1056.	1.3	20
14	The function of a novel immunophenotype candidate molecule PD-1 in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2015, 56, 2908-2913.	0.6	18
15	Tumor necrosis factor receptors (TNFRs) on T lymphocytes and soluble TNFRs in different clinical courses of sarcoidosis. Respiratory Medicine, 2007, 101, 645-654.	1.3	17
16	High M-MDSC Percentage as a Negative Prognostic Factor in Chronic Lymphocytic Leukaemia. Cancers, 2020, 12, 2614.	1.7	16
17	The Yield of Endobronchial Biopsy in Pulmonary Sarcoidosis: Connection between Spirometric Impairment and Lymphocyte Subpopulations in Bronchoalveolar Lavage Fluid. Respiration, 2004, 71, 72-76.	1.2	13
18	Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group. Leukemia and Lymphoma, 2017, 58, 2089-2100.	0.6	12

#	Article	IF	Citations
19	Intracellular ILâ€‘4 and IFNâ€Î³ expression in iNKT cells from patients with chronic lymphocytic leukemia. Oncology Letters, 2018, 15, 1580-1590.	0.8	12
20	1q21 amplification with additional genetic abnormalities but not isolated 1q21 gain is a negative prognostic factor in newly diagnosed patients with multiple myeloma treated with thalidomide-based regimens. Leukemia and Lymphoma, 2012, 53, 2500-2503.	0.6	10
21	The Impact of the NOD2/CARD15 Variant (3020insC) and PSMA6 Polymorphism (-8C>G) on the Development and Outcome of Multiple Myeloma. BioMed Research International, 2020, 2020, 1-15.	0.9	9
22	Assessment of the pathway of apoptosis involving PAR-4, DAXX and ZIPK proteins in CLL patients and its relationship with the principal prognostic factors. Folia Histochemica Et Cytobiologica, 2011, 49, 98-103.	0.6	8
23	Danazol induces apoptosis and cytotoxicity of leukemic cells alone and in combination with purine nucleoside analogs in chronic lymphocytic leukemia. Annals of Hematology, 2016, 95, 425-435.	0.8	7
24	Polymorphisms in the promotor region of the <scp>CRBN</scp> gene as a predictive factor for peripheral neuropathy in the course of thalidomideâ€based chemotherapy in multiple myeloma patients. British Journal of Haematology, 2019, 186, 695-705.	1.2	7
25	Assessment of microRNA expression in leukemic cells as predictors of sensitivity to purine nucleoside analogs, fludarabine and cladribine, in chronic lymphocytic leukemia patients . Cancer Management and Research, 2019, Volume 11, 5021-5031.	0.9	6
26	Cytotoxic Activity of Valproic Acid on Primary Chronic Lymphocytic Leukemia Cells. Advances in Clinical and Experimental Medicine, 2015, 24, 55-62.	0.6	6
27	Polymorphisms in the promoter region of the CRBN gene as a predictive factor for the first-line CTD therapy in multiple myeloma patients. Oncotarget, 2018, 9, 24054-24068.	0.8	6
28	Molecular Biology Methods in the Diagnosis of Multiple Myeloma. Principles and Practice, 2012, , 443-449.	0.3	5
29	Assessment of micro RNAs expression in leukemic cells as prognostic markers in chronic lymphocytic leukemia: micro RNAs can predict survival in a course of the disease. Oncotarget, 2018, 9, 19136-19146.	0.8	5
30	JAK2 mutation status, hemostatic risk factors and thrombophilic factors in essential thrombocythemia (ET) patients. Folia Histochemica Et Cytobiologica, 2011, 49, 267-271.	0.6	5
31	Association of Common Variants of TNFSF13 and TNFRSF13B Genes with CLL Risk and Clinical Picture, as Well as Expression of Their Productsâ€”APRIL and TACI Molecules. Cancers, 2020, 12, 2873.	1.7	4
32	Richter syndrome: A rare complication of chronic lymphocytic leukemia or small lymphocytic lymphoma. Advances in Clinical and Experimental Medicine, 2018, 27, 1683-1689.	0.6	4
33	Circulating Serum MiRNA-8074 as a Novel Prognostic Biomarker for Multiple Myeloma. Cells, 2022, 11, 752.	1.8	4
34	Thalidomide can promote erythropoiesis by induction of STAT5 and repression of external pathway of apoptosis resulting in increased expression of GATA-1 transcription factor. Pharmacological Reports, 2015, 67, 1193-1200.	1.5	3
35	Prognostic significance of isochromosome 17q in hematologic malignancies. Oncotarget, 2021, 12, 708-718.	0.8	3
36	Prognostic Value of Tie2-Expressing Monocytes in Chronic Lymphocytic Leukemia Patients. Cancers, 2021, 13, 2817.	1.7	3

#	Article	IF	Citations
37	TP53 polymorphism in plasma cell myeloma. Folia Histochemica Et Cytobiologica, 2018, 55, 203-211.	0.6	3
38	Assessment of Peripheral Blood and Bone Marrow Cells Apoptosis Caused by Purine Analogues in Patients with Chronic Lymphocytic Leukemia in Correlation with Parameters of Disease Progression. Acta Haematologica, 2010, 123, 171-178.	0.7	2
39	The rate of in vitro fludarabine-induced peripheral blood and bone marrow cell apoptosis may predict the chemotherapy outcome in patients with chronic lymphocytic leukemia. European Journal of Clinical Pharmacology, 2015, 71, 1121-1127.	0.8	2
40	The Relationship of ABCB1/MDR1 and CYP1A1 Variants with the Risk of Disease Development and Shortening of Overall Survival in Patients with Multiple Myeloma. Journal of Clinical Medicine, 2021, 10, 5276.	1.0	2
41	Analysis of ex vivo Apoptosis of B and T cells from Peripheral Blood and Bone Marrow of Patients with Chronic Lymphocytic Leukemia. Acta Haematologica Polonica, 2012, 43, 336-341.	0.1	1
42	Intracellular cytokine expression in T cells from patients with chronic lymphocytic leukemia. Acta Haematologica Polonica, 2013, 44, 319-325.	0.1	0
43	Efficacy of ixazomib-lenalidomide-dexamethasone in high-molecular-risk relapsed/refractory multiple myeloma â€“ case series and literature review. Annals of Agricultural and Environmental Medicine, 2021, 29, 103-109.	0.5	0
44	Skuteczne leczenie ibrutynibem chorego na przewlekÅ‚Ä… biaÅ‚aczkÄ… limfocytowÄ… z obecnoÅ›ciÄ… delecji 17p â€“ opis przypadku. Acta Haematologica Polonica, 2018, 49, 251-256.	0.1	0